Education
About Us
Working with TipRanks
Follow Us
Biophytis (BPTSY)
OTHER OTC:BPTSY
BPTSY Stock Chart & Stats
$0.74
-$1.35(-31.02%)
At close: 4:00 PM EST
$0.74
-$1.35(-31.02%)
Day’s Range― - ―
52-Week Range$0.54 - $3.45
Previous CloseN/A
Volume804.00
Average Volume (3M)52.00
Market Cap
$3.07M
Enterprise Value$7.59M
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$9.12M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,469,740
10 Day Avg. Volume88
30 Day Avg. Volume52
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.60
Price to Sales (P/S)0.00
P/FCF Ratio-1.79
Enterprise Value/Market Cap2.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.56
Enterprise Value/Ebitda-1.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.02
Revenue Forecast (FY)$2.36M
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineBiophytis is a clinical-stage biotech focused on age-related diseases with a clear lead program (Sarconeos/BIO101). A focused R&D portfolio concentrates resources on a single high-value indication, preserving capital and management attention to advance trials and partner/licence outcomes.
Narrowing Operating LossesThe company materially reduced losses and improved EBIT year-over-year, reflecting durable cost control and tighter spending discipline. Sustained reduction in cash burn lowers near-term financing needs and suggests management can extend runway while advancing clinical programs.
Shareholder Approval For Strategic ActionsRecent shareholder approval of AGM resolutions (noted with a ~31% quorum) provides governance backing to execute financing, licensing or restructuring plans. This structural support improves the company's ability to implement strategic moves to fund and advance development programs.
Bears Say
No Revenue / No Commercial ProductBiophytis has no product revenues and remains pre-commercial, meaning its long-term viability depends on clinical/regulatory success or partnerships. This structural absence of recurring revenue increases execution risk and prolongs reliance on external funding to sustain operations.
Negative Equity And Rising DebtNegative equity and an increase in total debt signal balance-sheet fragility and limited solvency cushions. Structurally weak equity positions constrain financing options, can force dilutive capital raises or costly credit, and reduce flexibility to absorb trial setbacks or invest opportunistically.
Persistent Cash Burn And FCF DeficitOperating and free cash flow remain meaningfully negative despite improvement, indicating core activities consume cash. Ongoing cash burn creates structural dependence on external financings, elevating dilution risk and potentially forcing timing-driven strategic compromises.
Biophytis News
BPTSY FAQ
What was Biophytis’s price range in the past 12 months?
Biophytis lowest stock price was $0.54 and its highest was $3.45 in the past 12 months.
What is Biophytis’s market cap?
Biophytis’s market cap is $3.07M.
When is Biophytis’s upcoming earnings report date?
Biophytis’s upcoming earnings report date is Nov 03, 2026 which is in 239 days.
How were Biophytis’s earnings last quarter?
Currently, no data Available
Is Biophytis overvalued?
According to Wall Street analysts Biophytis’s price is currently Overvalued.
Does Biophytis pay dividends?
Biophytis does not currently pay dividends.
What is Biophytis’s EPS estimate?
Biophytis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biophytis have?
Biophytis has 140,469,740 shares outstanding.
What happened to Biophytis’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biophytis?
Currently, no hedge funds are holding shares in BPTSY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biophytis
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Technical Analysis
Oragenics
―
InMed Pharmaceuticals
―
Pasithea Therapeutics Corp
―
SciSparc Ltd.
―
Onconetix
―